BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31688415)

  • 1. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    Perri T; Farhadian Y; Friedman E; Korach J
    Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
    Breda AS; Blaakær J
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
    Palaia I; Caruso G; Di Donato V; Turetta C; Savarese A; Perniola G; Gallo R; Giannini A; Salutari V; Bogani G; Tomao F; Giannarelli D; Gentile G; Musella A; Muzii L; Pignata S;
    J Gynecol Oncol; 2024 May; 35(3):e70. PubMed ID: 38497108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Chiariello G; Lepera A; Cazzato G; Cascardi E; Damiani GR; Cicinelli E; Cormio G
    Hormones (Athens); 2023 Mar; 22(1):19-23. PubMed ID: 36637775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
    Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
    Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
    Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.
    DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark M; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
    Menopause; 2023 Jul; 30(7):732-737. PubMed ID: 37192837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
    Birrer N; Chinchilla C; Del Carmen M; Dizon DS
    Am J Clin Oncol; 2018 Mar; 41(3):313-315. PubMed ID: 26840041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    Mejia-Gomez J; Gronwald J; Senter L; Karlan BY; Tung N; Wolfman W; Demsky R; Sun P; Narod SA; Kotsopoulos J;
    Menopause; 2020 Dec; 27(12):1396-1402. PubMed ID: 32796289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.